Listen and follow our podcasts on:

This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology

In this podcast series, Prof. Shaheenah Dawood and Assoc. Prof. Rena Callahan discuss oral SERDs for ER+/HER2- advanced or metastatic breast cancer.

 

Episode 1: Oral SERDs in ER+ breast cancer: efficacy, safety and treatment landscape

The experts explore the efficacy and safety profiles of oral SERDs and their place in the treatment landscape, and discuss how to optimise treatment selection and make appropriate sequencing decisions.

 

Episode 2: Oral SERDs in ER+ breast cancer: treatment selection and beyond

A deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments.

 

Episode 3: Oral SERDS in ER+ breast cancer: rare cases & treatment challenges

Prof. Dawood and Assoc. Prof. Callahan discuss the next two patient case studies of ER+/HER2- metastatic breast cancer, each presenting unique and rare situations that shed a light on the challenges confronting healthcare professionals and patients alike.

 

 

Clinical Takeaways

 

  • Elacestrant was the 1st oral SERD to be FDA approved (January 2023), with optimal efficacy and manageable safety for patients with ESR1 mutated ER+/HER2- advanced or metastatic breast cancer

  • Factors such as disease progression, tumour burden, treatment-related toxicities, patient preferences and quality of life should be considered when deciding whether to adjust current treatment dosage or switch therapies

  • Maximising endocrine therapy options is recommended with and without targeted therapy in ER+/HER2- advanced or metastatic breast cancer

  • ESR1 mutation testing should be done with a liquid biopsy platform at the time of progression on an aromatase inhibitor as well as after subsequent lines of progression

  • Oral SERDs are being studied as a monotherapy and in combination with targeted therapies (i.e. CDK4/6, PI3K and AKT inhibitors), offering promising prospects for their integration into clinical practice

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma

Rena D. Callahan, MD, is Associate Clinical Professor of Health Sciences in the Division of Hematology-Oncology in the Department of Medicine at the University of Los Angeles, California (UCLA) David Geffen School of Medicine. She received her undergraduate degree from Yale University, and her medical degree from the University of Pennsylvania in Philadelphia, before completing an internship and residency in Internal Medicine and a fellowship in Hematology-Oncology at UCLA. Dr Callahan is board-certified in Internal Medicine, Medical Oncology, and Hematology. Dr Callahan is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the American College of Physicians. She has served as principal or sub-investigator for numerous clinical research trials exploring topics related to breast cancer. Dr Callahan is a frequent lecturer on a variety of breast cancer topics and is focused on providing patient centered clinical care in the context of a large clinical practice.

Assoc. Clinical Professor Rena Callahan has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Support provided as a speaker from: Gilead, Lilly, Stemline, Seagen

Programme summary
Listen to the podcast now
Other episodes in this series
Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 1: Efficacy, safety and treatment landscape

Oral SERDs in ER+ breast cancer

Oral SERDs in ER+ breast cancer

Episode 2: Treatment selection and beyond

Oral SERDS in ER+ breast cancer

Oral SERDS in ER+ breast cancer

Episode 3: Rare cases & treatment challenges

Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
Precision oncology in prostate and gastric cancer: tips for optimal genomic testing

From sample collection through to diagnostic modalities 

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
podcast Podcast

Episode

2

of 2

episode
Oncology 
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Medical experts discuss how to approach sequencing in clinical practice

Experts
Prof. Arndt Vogel, Dr Lorenza Rimassa, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery Global Liver Institute
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
Testing to treatment of BRAF-mutant metastatic NSCLC

Medical experts share their insights on testing and treatment

Experts
Prof. David Planchard, Dr Federico Cappuzzo
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. This content is intended for HCPs outside the UK & ROI only.
podcast Podcast

Episode

1

of 2

episode
Oncology 
HCC podcast series part 1: The use of IO in unresectable HCC

Medical experts discuss safety and efficacy of IO and IO combinations, clinical trial data, and best practice

Experts
Dr Rachna Shroff, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The emerging role of artificial intelligence in precision oncology

Expert opinion on the clinical application of artificial intelligence (AI)

Experts
Prof. Albrecht Stenzinger
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology 
BRAF-mutated CRC: from testing to treatment

Medical experts share insights and review key clinical trials

Experts
Prof. Sebastian Stintzing, Dr Thomas Winder
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Nov 2024

Educational programme supported by an Independent Educational Grant from Pierre Fabre. This content is not intended for HCPs within the UK.